Developing tests for early detection of aggressive prostate cancer
Biomarker Developmental Laboratory
This study is working on new tests to help find aggressive prostate cancer early, so that patients can get personalized care based on their unique genetic markers, ultimately aiming to improve treatment outcomes for those at risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10891588 on NIH RePORTER |
What this research studies
This research focuses on creating and validating clinical-grade tests to detect aggressive prostate cancer at an early stage. The project involves a collaboration between the University of Michigan and Vanderbilt University Medical Center, along with industry partners, to enhance existing biomarkers and develop new ones. Patients will benefit from tests that provide personalized risk assessments based on specific genetic markers, which can guide treatment decisions. The goal is to improve early detection and treatment outcomes for those at risk of lethal prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research include men at risk for prostate cancer, particularly those with a family history or specific genetic markers associated with aggressive forms of the disease.
Not a fit: Patients who do not have prostate cancer or those with indolent forms of the disease that do not require aggressive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and earlier detection of aggressive prostate cancer, improving treatment options and outcomes for patients.
How similar studies have performed: Previous research has successfully identified biomarkers for prostate cancer detection, indicating that this approach has potential for further advancements.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Chinnaiyan, Arul M — University of Michigan at Ann Arbor
- Study coordinator: Chinnaiyan, Arul M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.